Abstract
A panel of advisers to the US Food and Drug Administration last week unanimously rejected an experimental testosterone patch as a treatment for women with sexual difficulties.
Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.”
Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.”
| Original language | English |
|---|---|
| Pages (from-to) | 1363-1363 |
| Number of pages | 1 |
| Journal | BMJ (Clinical research ed.) |
| Volume | 329 |
| Issue number | 7479 |
| DOIs | |
| Publication status | Published - 11 Dec 2004 |